Therapeutic safety monitoring: What to look for and when to look for it

Epilepsia

Volumn 41, Issue SUPPL. 8, 2000, Pages

  Harden, Cynthia L ^a  

^a NEW YORK PRESBYTERIAN HOSPITAL   (United States)

Author keywords

Adverse effect; Allergic reaction; Endocrine abnormalities; Stevens Johnson syndrome

Indexed keywords

AMMONIA; ANTICONVULSIVE AGENT; CARBAMAZEPINE; FELBAMATE; PHENYTOIN; VALPROIC ACID;

APLASTIC ANEMIA; BONE METABOLISM; DRUG EFFECT; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG SURVEILLANCE PROGRAM; DRUG USE; EPILEPSY; FEVER; HUMAN; LIVER TOXICITY; MULTIPLE ORGAN FAILURE; NERVE CONDUCTION; PERIPHERAL NERVE; PRIORITY JOURNAL; RASH; REVIEW; STEVENS JOHNSON SYNDROME; THROMBOCYTOPENIA; THYROID FUNCTION TEST; TOXIC EPIDERMAL NECROLYSIS;

EID: 0033759937     PISSN: 00139580     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1528-1157.2000.tb02945.x     Document Type: Review

References (103)

1. Phenytoin: Toxicity
2. Incidence and severity of phenytoin-induced gingival overgrowth in epileptic patients in general medical practice
3. Incidence of diphenylhydantoin gingival hyperplasia
4. Chronic antiepileptic drug toxicity: A review
5. Phenytoin-induced depression of salivary IgA and gingival hyperplasia
6. Subpopulations of lymphocytes in connective tissue from phenytoin-induced gingival overgrowth
7. The effect of dilantin upon fibroblast proliferation
8. Phenytoin-related cerebellar degeneration without seizures
9. Phenytoin: Toxicity
10. Cerebellar atrophy following acute intoxication with phenytoin
11. Cerebellar atrophy after acute phenytoin intoxication
12. Seasonal incidence of phenytoin allergy unrelated to plasma levels
13. Connective tissue changes, hypersensitivity, rash and blood laboratory test changes associated with antiepileptic drug therapy
14. Phenytoin hypersensitivity: 38 Cases
15. Phenytoin hepatotoxicity: A case report and review
16. Phenytoin: Hematologic toxicity
17. Carbamazepine
18. Hepatotoxic reactions associated with carbamazepine
19. Carbamazepine effects on mononuclear blood cells in epileptic patients
20. Tegretol in trigeminal neuralgia with special references to hematopoietic adverse effects
21. Carbamazepine and hematologic monitoring
22. Hyponatremia during carbamazepine therapy
23. Perspective on carbamazepine-induced water intoxication: Reversal by demeclocycline
24. Carbamazepine. Pharmacology and clinical uses
25. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic-clonic seizures
26. A comparison of valproate with carbamazepine for the treatment of partial seizures and secondarily generalized tonic-clonic seizures in adults
27. Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy
28. Carbamazepine adverse effects in children and adults
29. Antiepileptics and blood dyscrasias: A cohort study
30. The hyperkinetic syndrome in epileptic children
31. Psychology, Pharmacotherapy, and new diagnostic approaches
32. Phenobarbital: Toxicity
33. Chronic antiepileptic toxicity: A review
34. Delayed reaction to PRM in pregnancy
35. Exfoliative dermatitis and hepatitis due to phenobarbital
36. Macrocytosis and macrocytic anemia caused by anticonvulsant drugs
37. Asymptomatic hyperammonemia in patients receiving valproic acid
38. Valproate-induced inhibition of urea synthesis and hyperammonemia in healthy subjects
39. Evidence of inherited urea cycle defect in a case of fatal valproate toxicity
40. Valproate
41. Thrombocytopenia secondary to high valproate levels in children with epilepsy
42. Valproate therapy induces von Willebrand disease type I
43. Induction of von Willebrand disease type I by valproic acid
44. Valproate treatment and platelet function: The role of arachidonate metabolites
45. Influence of valproate monotherapy on platelet activation and hematologic values
46. Syndrome d'hypersensibilite medicamenteuse au cours d'un traitement par acide valproique
47. Valproate-associated pancreatitis
48. Valproic acid: Toxicity
49. Cytochrome P450-catalyzed formation of VPA, a toxic metabolite of valproic acid
50. Valproic acid hepatic fatalities: A retrospective review
51. Fatal liver failure in 16 children with valproate therapy
52. Valproic acid hepatic fatalities II: US experience since 1984
53. Changes in body weight with chronic, high-dose gabapentin therapy
54. Gabapentin toxicity in children manifesting as behavioral changes
55. Evaluation of gabapentin in an outpatient and office-based sample of epilepsy patients
56. Lamotrigine associated with insomnia
57. Positive and negative psychotropic effects of lamotrigine in patients with epilepsy and mental retardation
58. Adding lamotrigine to valproate: Incidence of rash and other adverse effects
59. Safety of long-term lamotrigine in epilepsy
60. Safety review of adult clinical trial experience with lamotrigine
61. Lamotrigine for the treatment of epilepsy in childhood
62. Allergic skin rash with lamotrigine and concomitant valproate therapy
63. Lamotrigine in treatment of 120 children with epilepsy
64. Phenytoin-like hypersensitivity associated with lamotrigine
65. Fulminant hepatic failure induced by lamotrigine
66. Antiepileptic drug hypersensitivity syndrome
67. Mechanisms of idiosyncratic hypersensitivity reactions to antiepileptic drugs
68. An audit of topiramate use in a general neurology clinic
69. Double-blind, placebo-controlled trial of topiramate as add-on therapy in patients with refractory partial seizures
70. Safety of topiramate: Adverse events and relationships to dosing
71. Safety of tiagabine: Summary of 53 trials
72. Tiagabine: The safety landscape
73. Evaluations of the incidence of status epilepticus in association with tiagabine therapy
74. Nonconvulsive status epilepticus in two patients receiving tiagabine treatment
75. Two cases of nonconvulsive status epilepticus in association with tiagabine therapy
76. Tiagabine and non-convulsive status epilepticus
77. Clinical and EEG findings in complex partial status epilepticus with tiagabine
78. Tiagabine and non-convulsive status epilepticus
79. Tiagabine-induced absence status in idiopathic generalized epilepsy
80. Extracellular GABA in the ventrolateral thalamus of rats exhibiting spontaneous absence epilepsy: A microdialysis study
81. Oxcarbazepine
82. Zonisamide
83. Vigabatrin
84. Results of a multicenter, placebo-controlled, parallel study of vigabatrin (VGB, Sabril) in patients with focal epilepsy whose seizures are difficult to control
85. A double-blind placebocontrolled study of vigabatrin three g/day in patients with uncontrolled complex partial seizures
86. Vigabatrin-associated retinal cone system dysfunction: Electroretinogram and ophthalmologic findings
87. Vigabatrin, a GABA-ergic antiepileptic drug, causes concentric visual field defects
88. Effect of carbamazepine, phenytoin and phenobarbitone on serum levels of thyroid hormones and thyrotropin in humans
89. Serum hormones in male epileptic patients receiving anticonvulsant medication
90. Multiple effects of 5,5-diphenylhydantoin on the thyroid hormone system
91. Changes in thyroid function tests induced by 2-month carbamazepine treatment in L-thyroxine-substituted hypothyroid children
92. Bone mineral density in AED treated women with epilepsy
93. Bone status after long-term anticonvulsant therapy in epileptic patients: Evaluation using quantitative ultrasound of calcaneous and phalanges
94. Chronic anticonvulsive therapy, peripheral nerve conduction velocity, and EMG
95. Anticonvulsant therapy and its possible consequences on peripheral nervous system: A neurographic study
96. Evaluation of the status of peripheral nerves in patients on long-term treatment with anticonvulsants based on a study of H reflex and F wave
97. Peripheral neuropathy in long-term diphenylhydantoin therapy
98. Elevated plasma concentrations of homocysteine in antiepileptic drug treatment
99. Plasma total homocysteine concentrations in epileptic patients taking anticonvulsants